Compare DSGN & NBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSGN | NBBK |
|---|---|---|
| Founded | 2017 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 853.8M | 926.5M |
| IPO Year | 2021 | 2023 |
| Metric | DSGN | NBBK |
|---|---|---|
| Price | $13.95 | $20.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $15.25 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 989.5K | 246.9K |
| Earning Date | 04-28-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.43% |
| EPS Growth | N/A | ★ 25.23 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $45.15 |
| Revenue Next Year | N/A | $4.18 |
| P/E Ratio | ★ N/A | $57.94 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $16.76 |
| 52 Week High | $17.25 | $22.86 |
| Indicator | DSGN | NBBK |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 52.92 |
| Support Level | $9.78 | $20.15 |
| Resistance Level | $16.69 | $21.76 |
| Average True Range (ATR) | 1.15 | 0.45 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 24.86 | 37.58 |
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.